Drug Trial Radar · NCT06401616
Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,220
Planned (sponsor's estimate)
Start
May 21, 2024
Primary completion
Mar 1, 2028
Study completion Mar 1, 2028
Sponsor
- Lead sponsor
- Odense University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Copenhagen University Hospital, Rigshospitalet; Gødstrup Hospital; Aarhus University Hospital; Aalborg University Hospital; Population Health Research Institute; Region of Southern Denmark
- First posted
- May 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Left atrial appendage (LAA) closure has become a frequent addition to oral anticoagulation in patients with atrial fibrillation who undergo cardiac surgery. The procedure significantly reduces the risk of stroke and systemic embolism, which may render anticoagulation unnecessary or even harmful when considering the associated increased risk of bleeding. A clinical trial to address the need for anticoagulation after LAA closure is needed. The ATLAAC trial will enroll 1220 patients with atrial fibrillation who have previously undergone surgical LAA closure. Patients will undergo a cardiac CT-scan to determine if LAA closure was successful and patients with successful closure will be randomized to continue or discontinue anticoagulation. The trial will assess the risk of ischemic stroke, peripheral arterial embolism, and major bleeding during the randomized intervention
Conditions
- Atrial Fibrillation
- Left Atrial Appendage Absent
- Anticoagulant Adverse Reaction
Interventions
OAC will be discontinued for the duration of the trialDrug
Discontinuation of warfarin, dabigatran, rivaroxaban, apixaban or edoxaban
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with ischemic strokes, peripheral arterial embolisms and major bleedingsTime frame: After 128 primary outcome events (approx 4 years)
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Rigshospitalet
Copenhagen, Capital Region, Denmark · Not yet recruiting
Gentofte Hospital
Gentofte Municipality, Capital Region, Denmark · Recruiting
Regionshospital Gødstrup
Herning, Central Jutland, Denmark · Not yet recruiting
Aalborg university hospital
Aalborg, North Denmark, Denmark · Not yet recruiting
Århus Universitetshospital
Aarhus, Region Midt, Denmark · Recruiting
Odense University Hospital
Odense, Region Syddanmark, Denmark · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.